

5an101ME
5an180ME
5an048ME
5an179ME
5an178ME
2 distinct anti-C5a epitopes
2 distinct anti-C5/C5a epitopes

Fig. 1



Anti-C5 Ab
BNJ367
BNJ369
BNJ371
BNJ378
BNJ381
BNJ383
OD
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.08
0.4
2
10
[Ab](nM)

Fig. 2



5an195ME (n=5)
Control Ab (n=5)
Thickness (mm)
5.5
5
4.5
4
3.5
Day After Disease Onset
0
2
4
6
8
10
12
14

Fig. 3



5an195ME (n=6)
Control Ab (n=6)
Arthritis Index
Day After Disease Onset
0
1
2
3
4
5
6
7
8
9
10
0
2
4
6
8
10
12
14

Fig. 4



HC FR1
HC FR2
HC CDR1
HC FR3
HC FR4
HC CDR2
HC CDR3
SIN:76 QVQLVQSGSELKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMG
SIN:77 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWVG
SIN:78 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQASGKGLEWMG
SIN:79 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQASGKGLEWMG
SIN:80 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWVG
AIHLNTGYTNYNQKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAR-GFYDGYSPMDYWGQGTTVTVSS
AIHLNTGYTNYNQKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAR-GFYDGYSPMDYWGQGTTVTVSS
AIHLNTGYTNYNQKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAR-GFYDGYSPMDYWGQGTTVTVSS
AIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR-GFYDGYSPMDYWGQGTTVTVSS
AINPNSGGTNYSQKFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARSGSYDGYYAMDYWGQGTTVTVSS

Fig. 5



Control ab
24 mg/mL
12 mg/mL
6 mg/mL
3 mg/mL
sham
BNJ383
sham
BNJ383, 24 mg/kg
BNJ383, 12 mg/kg
BNJ383, 6 mg/kg
BNJ383, 3 mg/kg; control ab
% Baseline (Neutrophil)
120
100
80
60
40
20
0
0 min
1 min
3 min
5 min
Time

Fig. 6



MPO (ng/mL)
300
250
200
150
100
50
0
Sham
Control mAb
BNJ383, 3 mg/kg
BNJ383, 6 mg/kg
BNJ383, 12 mg/kg
BNJ383, 24 mg/kg
0 min
5 min
TIME

Fig. 7



sham
control mAb
BNJ383
3 mg/kg
6 mg/kg
12 mg/kg
24 mg/kg
C5a Concentration (ng/mL)
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
0 min
1 min
3 min
5 min
Time
control mAb
BNJ383, 3 mg/kg
BNJ383, 6 mg/kg
BNJ383, 12 mg/kg
BNJ383, 24 mg/kg
sham

Fig. 8



Balb/C plasma
DBA/2J plasma
Cynomolgus macaque plasma
Human plasma
Human C5a desarg
RU
100000
10000
1000
100
0.1
1
100
1000
[Antigen nM]

Fig. 9



BNJ383
anti-C5
CAP Activity (%BL)
120
100
80
60
40
20
0
-20
0.0001
0.001
0.01
0.1
1
10
100
Concentration (µM)

Fig. 10



BNJ383
anti-C5
CCP Activity (%BL)
120
100
80
60
40
20
0
-20
0.0001
0.001
0.01
0.1
1
10
100
Concentration (µM)

Fig. 11



BNJ383
10.246
AU
Minutes
0.016
0.014
0.012
0.010
0.008
0.006
0.004
0.002
0.000
-0.002
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
0.010
0.008
0.006
0.004
0.002
0.000
9.50
10.00
10.50
11.00

Fig. 12A



Anti-C5 mAb
10.172
AU
Minutes
0.055
0.050
0.045
0.040
0.035
0.030
0.025
0.020
0.015
0.010
0.005
0.000
-0.005
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
AU
Minutes
0.010
0.008
0.006
0.004
0.002
0.000
-0.002
9.50
10.00
10.50
11.00

Fig. 12B



AU
0.040
0.035
0.030
0.025
0.020
0.015
0.010
0.005
0.000
-0.005
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
Minutes
10.169
9.181
8.517
Ab or hC5
Ab:1hC5
Ab:2hC5
AU
0.010
0.008
0.006
0.004
0.002
0.000
8.00
9.00
10.00
11.00
Minutes

Fig. 12C



AU
0.26
0.24
0.22
0.20
0.18
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
Minutes
9.218
10.284
8.592
12.370
Ab:2hC5
Ab:1hC5
Ab or hC5
AU
0.004
0.002
0.000
8.00
10.00
12.00
Minutes

Fig. 12D



Binding of BNJ383 to hC5a desArg in the presence of C5
BNJ383
BNJ383 + C5
OD450 reading
BNJ383 ng/ml
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0.1
1
10
100

Fig. 13



C5a (pg/mL)
4500
4000
3500
3000
2500
2000
1500
1000
500
0
BNJ383 (µg/mL)
0
1
10
100
1,000
10,000

Fig. 14



Hemolytic Activity (% baseline)
120
100
80
60
40
20
0
0
1
10
100
1,000
10,000
BNJ383 (µg/mL)

Fig. 15A



CH50-Eq (% of baseline)
120
100
80
60
40
20
0
0
1
10
100
1,000
10,000
BNJ383 (µg/mL)

Fig. 15B



CCP activity (% of baseline)
120
100
80
60
40
20
0
0
1
10
100
1,000
10,000
BNJ383 (µg/mL)

Fig. 15C